25 years of Bayesian methods in the pharmaceutical industry: a personal, statistical bummel

Twenty-five years ago the use of Bayesian methods in Pharmaceutical R&D was non-existent. Today that is no longer true. In this paper I describe my own personal journey along the road of discovery of Bayesian methods to routine use in the pharmaceutical industry.

[1]  J. Grizzle.  THE TWO-PERIOD CHANGE-OVER DESIGN AN ITS USE IN CLINICAL TRIALS. , 1965, Biometrics.

[2]  L. Tierney,et al.  Accurate Approximations for Posterior Moments and Marginal Densities , 1986 .

[3]  A. Grieve,et al.  Tests of sphericity of normal distributions and the analysis of repeated measures designs , 1984 .

[4]  A. Grieve,et al.  Extending a Bayesian analysis of the two-period crossover to accommodate missing data , 1995 .

[5]  R. Davidson.  On Extending the Bradley-Terry Model to Accommodate Ties in Paired Comparison Experiments , 1970 .

[6]  M. West,et al.  Bayesian forecasting and dynamic models , 1989 .

[7]  B. Rodda,et al.  Determining the probability of an important difference in bioavailability , 1980, Clinical pharmacology and therapeutics.

[8]  David J. Spiegelhalter,et al.  Bayesian Approaches to Randomized Trials , 1994, Bayesian Biostatistics.

[9]  George E. P. Box,et al.  Sampling and Bayes' inference in scientific modelling and robustness , 1980 .

[10]  David Draper,et al.  Assessment and Propagation of Model Uncertainty , 2011 .

[11]  T. Olsen,et al.  Outcome and time course of recovery in stroke. Part I: Outcome. The Copenhagen Stroke Study. , 1995, Archives of physical medicine and rehabilitation.

[12]  A P Grieve,et al.  Predictive probability in clinical trials. , 1991, Biometrics.

[13]  D. Lindley,et al.  Approximate Bayesian methods , 1980 .

[14]  W. Gilks,et al.  Adaptive Rejection Sampling for Gibbs Sampling , 1992 .

[15]  J. Aitchison,et al.  Two Papers on the Comparison of Bayesian and , 1964 .

[16]  F. Harrell,et al.  USING FULL PROBABILITY MODELS TO COMPUTE PROBABILITIES OF ACTUAL INTEREST TO DECISION MAKERS , 2001, International Journal of Technology Assessment in Health Care.

[17]  A. F. Smith,et al.  Bayesian Methods in Practice: Experiences in the Pharmaceutical Industry , 1986 .

[18]  G. C. Tiao,et al.  Bayesian inference in statistical analysis , 1973 .

[19]  John A. Lewis.  Clinical trials: Statistical developments of practical benefit to the pharmaceutical industry , 1983 .

[20]  D. Spiegelhalter,et al.  Bayes Factors for Linear and Log‐Linear Models with Vague Prior Information , 1982 .

[21]  L. J. Wei,et al.  The Randomized Play-the-Winner Rule in Medical Trials , 1978 .

[22]  A P Grieve,et al.  Extending a Bayesian analysis of the two-period crossover to allow for baseline measurements. , 1994, Statistics in medicine.

[23]  Andrew P. Grieve,et al.  Implementation of Bayesian methods in the pharmaceutical industry , 1992 .

[24]  P. Thall,et al.  Practical Bayesian adaptive randomisation in clinical trials. , 2007, European journal of cancer.

[25]  V H PATIL,et al.  APPROXIMATION TO THE BEHRENS-FISHER DISTRIBUTIONS. , 1965, Biometrika.

[26]  Confidence intervals and sample sizes. , 1991, Biometrics.

[27]  Michael D. Smith,et al.  Adaptive Bayesian Designs for Dose-Ranging Drug Trials , 2002 .

[28]  J. Jerome.  Three Men on the Bummel , 1900 .

[29]  A P Grieve,et al.  Issues for statisticians in pharmaco-economic evaluations. , 1998, Statistics in medicine.

[30]  J. Geweke,et al.  Bayesian Inference in Econometric Models Using Monte Carlo Integration , 1989 .

[31]  H. Fluchler,et al.  An aid to decision-making in bioequivalence assessment , 1981, Journal of Pharmacokinetics and Biopharmaceutics.

[32]  A O'Hagan,et al.  Bayesian cost‐effectiveness analysis from clinical trial data , 2001, Statistics in medicine.

[33]  A P Grieve,et al.  A Bayesian analysis of the two-period crossover design for clinical trials. , 1985, Biometrics.

[34]  Measuring Your Posterior Beliefs that You Can Count Properly , 1994 .

[35]  Andrew P. Grieve,et al.  Applications of Bayesian software: two examples , 1987 .

[36]  S Senn,et al.  Estimating treatment effects in clinical crossover trials. , 1998, Journal of biopharmaceutical statistics.

[37]  Donald J. Schuirmann.  A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailability , 1987, Journal of Pharmacokinetics and Biopharmaceutics.

[38]  Andrew P Grieve,et al.  Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): An Adaptive Dose-Response Study of UK-279,276 in Acute Ischemic Stroke , 2003, Stroke.

[39]  Andrew P Grieve,et al.  ASTIN: a Bayesian adaptive dose–response trial in acute stroke , 2005, Clinical trials.

[40]  A. F. M. Smith,et al.  Some Bayesian Thoughts on Modelling and Model Choice , 1986 .

[41]  P F Thall,et al.  A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials. , 1998, Biometrics.

[42]  Testing Equivalence Simultaneously for Location and Dispersion of two Normally Distributed Populations , 1994 .

[43]  P. Wakker,et al.  Confidence intervals for cost/effectiveness ratios. , 1995, Health economics.

[44]  P. Freeman.  The performance of the two-stage analysis of two-treatment, two-period crossover trials. , 1989, Statistics in medicine.

[45]  W C Black,et al.  The CE Plane , 1990, Medical decision making : an international journal of the Society for Medical Decision Making.

[46]  A. Grieve.  Do statisticians count? A personal view , 2002 .

[47]  R. A. Bradley,et al.  RANK ANALYSIS OF INCOMPLETE BLOCK DESIGNS THE METHOD OF PAIRED COMPARISONS , 1952 .

[48]  P. Thall,et al.  Dose‐Finding Based on Efficacy–Toxicity Trade‐Offs , 2004, Biometrics.

[49]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[50]  W. Westlake,et al.  Symmetrical confidence intervals for bioequivalence trials. , 1976, Biometrics.

[51]  W. J. Westlake,et al.  Use of confidence intervals in analysis of comparative bioavailability trials. , 1972, Journal of pharmaceutical sciences.

[52]  J. Naylor,et al.  Applications of a Method for the Efficient Computation of Posterior Distributions , 1982 .

[53]  J. Sacristán,et al.  Use of Confidence Intervals and Sample Size Calculations in Health Economic Studies , 1995, The Annals of pharmacotherapy.

[54]  A. Grieve.  Bayesian analyses of two-treatment crossover studies , 1994, Statistical methods in medical research.

[55]  W. R. Thompson.  ON THE LIKELIHOOD THAT ONE UNKNOWN PROBABILITY EXCEEDS ANOTHER IN VIEW OF THE EVIDENCE OF TWO SAMPLES , 1933 .

[56]  J O'Quigley,et al.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.

[57]  A. Dempster,et al.  A Bayesian approach to bioequivalence for the 2 x 2 changeover design. , 1981, Biometrics.

[58]  L V Rubinstein,et al.  A comparison of two phase I trial designs. , 1994, Statistics in medicine.

[59]  S. E. Hills,et al.  Illustration of Bayesian Inference in Normal Data Models Using Gibbs Sampling , 1990 .

[60]  J. D. Haynes.  Statistical simulation study of new proposed uniformity requirement for bioequivalency studies. , 1981, Journal of pharmaceutical sciences.

[61]  A. Grieve.  A Note on the Analysis of the Two-Period Crossover Design When the Period-Treatment Interaction is Significant , 1987 .

[62]  D. Mandallaz,et al.  Comparison of different methods for decision-making in bioequivalence assessment. , 1981, Biometrics.

[63]  H Fluehler,et al.  Bayesian approach to bioequivalence assessment: an example. , 1983, Journal of pharmaceutical sciences.

[64]  S. Goodman,et al.  Some practical improvements in the continual reassessment method for phase I studies. , 1995, Statistics in medicine.

[65]  W C Blackwelder,et al.  "Proving the null hypothesis" in clinical trials. , 1981, Controlled clinical trials.

[66]  Chih-Ling Tsai.  A note on Jorgensen's iteratively defined statistics , 1994 .

[67]  Donald A. Berry,et al.  Simulation-based sequential Bayesian design , 2007 .

[68]  A. Grieve.  Joint equivalence of means and variances of two populations. , 1998, Journal of biopharmaceutical statistics.

[69]  A P Grieve,et al.  A two-stage procedure for bioequivalence studies. , 1987, Biometrics.

[70]  A P Grieve,et al.  On the construction of shortest confidence intervals and Bayesian highest posterior density intervals. , 1991, Journal of veterinary pharmacology and therapeutics.

[71]  Andrew P. Grieve.  A further note on sampling to locate rare defectives with strong prior evidence , 1994 .

[72]  C M Metzler,et al.  Bioavailability--a problem in equivalence. , 1974, Biometrics.

[73]  S Zacks,et al.  Cancer phase I clinical trials: efficient dose escalation with overdose control. , 1998, Statistics in medicine.

[74]  Adrian F. M. Smith,et al.  Efficient generation of random variates via the ratio-of-uniforms method , 1991 .

[75]  M. Selwyn,et al.  On Bayesian methods for bioequivalence. , 1984, Biometrics.

[76]  I. Guttman.  The Use of the Concept of a Future Observation in Goodness‐Of‐Fit Problems , 1967 .

[77]  Peter Müller,et al.  A Bayesian Decision-Theoretic Dose-Finding Trial , 2006, Decis. Anal..

[78]  Andrew P Grieve,et al.  Implementation of a Bayesian adaptive design in a proof of concept study , 2006, Pharmaceutical statistics.

[79]  D. Ashby.  Bayesian statistics in medicine: a 25 year review , 2006, Statistics in medicine.

[80]  M. Drummond,et al.  Clinical importance, statistical significance and the assessment of economic and quality-of-life outcomes. , 1993, Health economics.

[81]  C. Chatfield.  Model uncertainty, data mining and statistical inference , 1995 .

[82]  Bernie J. O'Brien,et al.  In Search of Power and Significance: Issues in the Design and Analysis of Stochastic Cost-Effectiveness Studies in Health Care , 1994, Medical care.

[83]  M J Al,et al.  Costs, effects and C/E-ratios alongside a clinical trial. , 1994, Health economics.